|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01538238|
Recruitment Status : Completed
First Posted : February 24, 2012
Last Update Posted : April 26, 2017
Recent advances in understanding the biology and genetics of renal cell carcinoma (RCC) have led to major therapeutic implications. Von Hippel-Lindau (VHL) gene inactivation, present in the majority of sporadic forms of RCC, leads to a defective VHL protein, followed by an active transcription of hypoxia-inducible genes, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), c-kit, and others. However, the concept of VHL inactivation in RCC and the subsequent malignant phenotype is almost exclusively seen in patients with clear cell histology.
The data about efficacy of VEGF receptor inhibitors for non-clear cell RCC (NCRCC) is rare until now. Recently, however, sunitinib and sorafenib showed its worth for NCRCC in extended access programs.1-3 Although it is not certain, the underlying mechanism of their action might lie in that papillary, chromophobe, and sarcomatoid type overexpress c-kit, which is also a target of both drugs and could therefore provide a therapeutic target for non-clear cell subtypes.4-7 Pazopanib is also a potent and selective, orally available, small molecule inhibitor of VEGFR-1,-2, and -3, PDGF-α, PDGF-β, and c-kit tyrosine kinases. It has been validated and licensed for advanced clear cell RCC (CCRCC).8 However, there is very few data about its efficacy for NCRCC.
In this study, we try to evaluate the efficacy of pazopanib in metastatic NCRCC.
|Condition or disease||Intervention/treatment||Phase|
|Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma||Drug: pazopanib||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Actual Study Start Date :||May 2, 2012|
|Actual Primary Completion Date :||February 28, 2015|
|Actual Study Completion Date :||November 14, 2015|
pazopanib 800mg qd
pazopanib 800mg qd until progression or unacceptable toxicity
- Overall response rates [ Time Frame: 2years ]
- Progression-free survival [ Time Frame: 2years ]
- Overall survival [ Time Frame: 2years ]
- Number of Adverse Events [ Time Frame: 2years ]
- Exploratory analysis [ Time Frame: 2years ]c-kit protein expression,the relationship between efficacy and tumoral fibroblast growth factor receptor 1 gene amplification (FISH), the relationship between efficacy and MET mutation in papillary carcinoma, the relationship between efficacy and microvessel density and/or VEGF-R2 expression in tumor by immunohistochemistry
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538238
|Korea, Republic of|
|Samsung medical Center|
|Seoul, Korea, Republic of|